Page 607«..1020..606607608609..620630..»

5 common nail concerns and what they could mean – Times of India

Posted: Published on September 26th, 2020

Have you been dealing with yellow and brittle nails? Continue reading

Posted in Ulcerative Colitis | Comments Off on 5 common nail concerns and what they could mean – Times of India

CureDuchenne Congratulates Dyne Therapeutics On Its Initial Public Offering – thepress.net

Posted: Published on September 26th, 2020

NEWPORT BEACH, Calif., Sept. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on CureDuchenne Congratulates Dyne Therapeutics On Its Initial Public Offering – thepress.net

Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Muscular Dystrophy – globenewswire.com

Posted: Published on September 26th, 2020

September 22, 2020 01:00 ET | Source: Santhera Pharmaceuticals Holding AG multilang-release Pratteln, Switzerland, September22, 2020 Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. and their academic collaborators have published new open-label, long-term clinical data on the safety, tolerability and efficacy of vamorolone in patients with Duchenne muscular dystrophy (DMD). These 18-month treatment data extend previously published 24-week treatment data, and show a reduction of corticosteroid-specific side effects and sustained efficacy with vamorolone including clinical improvement through the 18-month follow-up period Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Muscular Dystrophy – globenewswire.com

Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society…

Posted: Published on September 26th, 2020

September 23, 2020 09:25 ET | Source: Capricor Therapeutics --Final 12-Month Results from Phase II Trial to be Presented on October 1-- LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the Company will present novel data from its randomized, double-blind, Phase II HOPE-2 clinical trial with its lead investigational product, CAP-1002, in boys and young men with Duchenne muscular dystrophy (DMD) Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society…

Sarepta Therapeutics Inc. (NASDAQ:SRPT) Releases Update On SRP-9001 Gene Therapy Program In Duchenne Muscular Dystrophy Treatment – BP Journal

Posted: Published on September 26th, 2020

Sarepta Therapeutics Inc. (NASDAQ:SRPT) has announced the completion of a Type C written response only meeting with the FDAs Centre for Biologics Evaluation and Researchs (CBER) Office of Tissues and Advanced Therapies(OTAT) for SRP-9001. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Sarepta Therapeutics Inc. (NASDAQ:SRPT) Releases Update On SRP-9001 Gene Therapy Program In Duchenne Muscular Dystrophy Treatment – BP Journal

Dr Patricia Coyle Underscores the Importance of Diagnosing and Treating MS Early – ajmc.com

Posted: Published on September 24th, 2020

Emerging data is showing that treatment within 6 months of presentation of multiple sclerosis (MS) is ideal, explained Patricia K. Continue reading

Posted in MS Treatment | Comments Off on Dr Patricia Coyle Underscores the Importance of Diagnosing and Treating MS Early – ajmc.com

Safety Concern With Fingolimod to Ocrelizumab Switch in MS – Medscape

Posted: Published on September 24th, 2020

A new study suggeststhe need for caution in switching from fingolimod to a B celldepleting anti-CD20 treatment such as ocrelizumab for patients with multiple sclerosis (MS). Italian researchers report an increased risk for prolonged reductions in T-cell counts, in addition to depletion of B cells, among patients who make this switch. Such depletion could increase the risk for infection, a particular concern in the current COVID era Continue reading

Posted in MS Treatment | Comments Off on Safety Concern With Fingolimod to Ocrelizumab Switch in MS – Medscape

Biogen stands to lose billions in Tecfidera sales next year, analyst says after new court ruling – FiercePharma

Posted: Published on September 24th, 2020

Defending its blockbuster multiple sclerosis drug Tecfidera from generics hasn't been easy for Biogen lately, and the painful trend continuedthis week with a court ruling thatclears the way for more copycat drugs to launch. After the Delaware patent court loss this week, multiple generics will likely roll out soon, Bernstein analyst Ronny Galpredictsand when they do, they'll siphon off most of Tecfidera's $3 billion-plus in U.S. Continue reading

Posted in MS Treatment | Comments Off on Biogen stands to lose billions in Tecfidera sales next year, analyst says after new court ruling – FiercePharma

Extended-Release Amantadine Improves Walking Speed in Patients With MS – Neurology Advisor

Posted: Published on September 24th, 2020

The following article is part of conference coverage from the 8th Joint American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) MSVirtual2020 event. Neurology Advisors staff will be reporting breaking news associated with research conducted by leading experts in neurology. Continue reading

Posted in MS Treatment | Comments Off on Extended-Release Amantadine Improves Walking Speed in Patients With MS – Neurology Advisor

Hospital Urges Islanders to Keep Up With Preventive Health Care – The Vineyard Gazette – Martha’s Vineyard News

Posted: Published on September 24th, 2020

Marthas Vineyard Hospital leaders urged Vineyarders to not postpone care and to schedule flu shots as the fall begins, breathing a sigh of relief about the summer but preparing for the unknown months that lie ahead for homelessness and drug use prevention. During the hospitals biweekly press briefing Wednesday morning, president and chief executive officer Denise Schepici said there is evidence that patients are postponing care and arriving at the hospital with acute illnesses that require treatment off-Island. Continue reading

Posted in MS Treatment | Comments Off on Hospital Urges Islanders to Keep Up With Preventive Health Care – The Vineyard Gazette – Martha’s Vineyard News

Page 607«..1020..606607608609..620630..»